INTRODUCTION
Neuroblastoma (NB) is a malignant embryonal tumour of the autonomic nervous system derived from neural crest cells. It has the earliest incidence peak of childhood cancers and is the most frequent cancer in infants (aged less than one year). The median age at 1 diagnosis is 22 months, and 85 of cases are diagnosed before the age of 5 years. 2 12 The literature on pre-and perinatal factors in neuroblastoma is relatively limited and the results of the various studies are most often inconsistent. Pre-term (< 37 weeks) and post-term (> 41 weeks) birth, low birth weight (< 2500 grams) and high birth weight (> 4000 grams), have been associated with neuroblastoma, with positive or negative associations for the same risk factor, depending on the study.4
Maternal reproductive factors such as fetal losses or use of sex hormones have also been associated with neuroblastoma in some studies, -9 while others did not show any association. , 10-12 4-6 13 Birth defect constitutes the factor that has been most consistently positively associated with NB in several studies. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Very few papers have reported analyses by NB subgroups. Only the study by the Children s Oncology Group has suggested that ' associations with previous miscarriages and previous induced abortion may depend on MYCN oncogene amplification status.10
This study therefore investigated the role of birth-related characteristics, birth defects and maternal reproductive history in the etiology of neuroblastoma using the data generated by the ESCALE study. ESCALE is a French national population-based case-control study, which was carried out to assess the role of infectious, environmental and genetic factors in 4 childhood cancers: leukemia, lymphoma, malignant central nervous system tumor and neuroblastoma.
MATERIAL AND METHODS

Study population
Details of the study design have been provided elsewhere. Briefly, the cases were children under the age of 15 years, in whom 23 The eligibility criteria were the biological mother s availability for interview, a telephone in the home, the biological mother s ability to The controls were randomly selected from the general population using a sample of 60,000 phone numbers representative of the French population. Control selection was stratified using quotas ensuring frequency matching with cases by age and gender. The quotas were designed to be representative of all cancer cases in terms of age and gender. Additional quotas were designed to ensure that the control group was representative of the French population in terms of the number of children living in the household, conditionally on age group. Out of the 50,217 phone numbers called, 46,994 were non-eligible numbers (22,584 businesses or disconnected numbers, 18,456 household without children, 5,277 out of quotas, 677 non-reliable interviews). The eligibility of 862 phone numbers could not be determined. Finally, out of the 2361 remaining eligible controls, 1681 (71 ) were included in the study (679 parents refused and one child % had a prior history of neuroblastoma).
Data collection
All case and control mothers responded to a standardized telephone interview conducted by trained interviewers and lasting approximately 40 minutes. The cases mothers were interviewed at least 2 months after the diagnosis. The interview focused on
Maternal reproductive history included questions on maternal history of fetal losses defined as any pregnancy loss (spontaneous abortions, abortions and termination of pregnancy for medical reasons: congenital anomalies, chromosomal anomalies, German measles or toxoplasmosis) and the use of fertility treatments for the index child, such as ovarian stimulation, in vitro fertilization and artificial insemination.
Statistical analysis
All the analyses were performed using SAS software (version 9.1, Gary, NC, USA). Odds ratios and 95 confidence intervals were % estimated using unconditional logistic regression models including the stratification variables, gender and age. Because of the particular age distribution of NB, narrow age groups were defined in order to avoid possible residual confounding by age: 2, 4, 6, 8, 10, 12, 18, 24 months and 3, 4, 5 to 6, 7 to 8, 9 to 11 and 12 to 14 years. The analysis was also restricted to the subgroup aged less than 12 years given the small number of cases aged 12 or more years.
We also stratified the analyses by age (< 1 year / 1 year), known to be an important prognostic factor which may be of etiologic ≥ relevance.
Potential confounding by socioeconomic category, maternal educational level and maternal working during pregnancy was also considered in the various analyses.
Additional analyses were conducted by subgroups of NB defined by age at diagnosis (age < one year / age one year) and MYCN ≥ oncogene amplification status (amplified (MYCN )/non-amplified (MYCN )).
+ −
MYCN copy numbers were determined by the national laboratories of reference.
RESULTS
describes the study population. Of the 191 cases included, the MYCN oncogene was amplified (MYCN ) in 35 cases (18 ), Table 1 + % not amplified (MYCN ) in 144 cases (76 ) and not available for 12 cases (6 ).
− % %
The case and control gender distributions were similar ( ). The control group had the same age distribution as the whole table 1 ESCALE case population, but was older, on average, than the neuroblastoma group. However, there were at least two controls for each case in each age stratum. The cases and controls did not differ significantly with respect to familial status, maternal educational level, or maternal working during pregnancy ( ). Nonetheless, the case parents (25 ) were slightly more frequently factory and agricultural table 1 % workers or unemployed than the control parents (16 ) (p 0.04).
% =
shows the associations between birth-related characteristics and neuroblastoma. The case mothers were more often aged less Table 2 than 25 years at the index child s birth than the control mothers (OR 2.3, 95 CI: 1.5 3.6). No association between gestational age or ' = % -birth weight and neuroblastoma considered as a whole was observed. However, a U-curve between birth weight and MYCN NB cases irrespective of MYCN amplification status, it is noteworthy that, although only based on one case (3 ) and 14 controls (1 ), an elevated % % OR of 3.3 (95 CI: 0.4 30) was observed in MYCN cases when the medical reason for termination was congenital anomalies. Finally,
no association between neuroblastoma and the use of fertility treatments of any type (drug stimulation only, in vitro fertilization, artificial insemination) for the index child was evidenced (OR 0.9, 95 CI: 0.4 2.0).
presents the previous analyses stratified by age (< 1 year / 1 year). We did not find any association with none of the Table 5 ≥ investigated perinatal factors (birth weight, gestational age, congenital malformation, spontaneous abortion and the use of fertility treatments for index child) in children aged 1 year or more. Conversely, when analyses were restricted to children aged less than one year, we observed a U-shape association between neuroblastoma and birth weight (OR 4.8, 95 CI: 1.6 15 and OR 2.9, 95 CI: 1.0 8.0;
respectively for birth weight < 2930 grams and birth weight 3720 grams). Congenital malformations were also highly associated to ≥ neuroblastoma in children aged less than 1 year (OR 16.8, 95 CI: 3.1 90).
= % -
Adjustment for familial situation, maternal educational level and socioeconomic categories did not modify the results. The estimates also remained unchanged after mutual adjustments for the various variables of interest, but the association with high birth order lost its significance.
Lastly, excluding the 10 cases and 37 controls whose mothers did not have the children s health records available did not change the ' results.
DISCUSSION
ESCALE is the first French population-based case-control study including cases of frequent childhood neoplastic diseases (leukemia, lymphoma, brain tumor and neuroblastoma) on a national scale. The main results of the analysis were the positive association with congenital malformations, especially for cases with MYCN oncogene amplification, and the negative association with a maternal history of spontaneous abortions.
The size of the study enabled detection of minimum odds ratios of 1.6, 1.9 and 2.3 for exposure prevalences in controls of 30, 10 and five percent, respectively, with a type-I error of 5 percent and power of 80 percent.
Case identification was based on the network of investigators working with the two French National Registries of Childhood Cancer (RNHE and RNTSE), making a selection bias due to the case identification process unlikely. Over the two-year study period, 276 NB cases were identified. The number was equivalent to the expected incidence of NB in France.25
Out of the 276 cases identified, 41 were not eligible (20 were MYCN oncogene not amplified, 11 were MYCN oncogene amplified and 10 had MYCN oncogene status not informative). Twenty-two had died or were receiving palliative care. The non-inclusion of those 22 children may have induced survival bias. Indeed, those children were younger (average age of 1.5 versus 2.4 years, p 0.01) and more often = MYCN oncogene amplified (45 versus 18 , p 0.002) than included children. However, a history of malformation is unlikely to lead to a % % = better prognosis, and there is no obvious reason for a maternal history of miscarriages being related to a poorer prognosis. In addition, the prevalence of MYCN oncogene amplification, which is an important prognostic factor, was 18 percent, similar to that of the published clinical series. , Nineteen percent (n 44) of the eligible cases did not respond. However, the age and gender distributions of the 2 28 = respondent and non-respondent cases were similar. The controls were randomly selected from the general population using the national telephone directory as a random basis. Unlisted numbers were computer generated prior to the random selection in order to avoid listed-control selection bias. The sampling process also made the controls similar to the French population in terms of number of children living in the household and, subsequently, in terms of birth order, when compared with the national perinatal surveys. , The 29 30
comparison with those surveys also showed that the controls were very similar to the French population in terms of mother s educational The controls mothers were slightly older than in the overall population. In fact, only 10 of the control mothers were aged less than 25
' % years at the birth of the index child, compared to 17 and 19 in the 1998 and 2003 national surveys, respectively. Thus, the association % % observed between maternal age < 25 years at birth and neuroblastoma may be due to an underestimation of the number of young mothers among the controls. However, maternal age was not related to the variables of interest and adjustment on maternal age did not change any of the results.
The control mothers were very similar to the case mothers with respect to their familial situation, educational level and working during pregnancy, but their socioeconomic categories were slightly higher. However, the results remained unchanged after additional adjustment for those factors.
The use of standardized questionnaires and the similar interviewing conditions for case and control mothers reduced potential differential misclassifications. In order to facilitate recall and increase efficiency, at the beginning of the interview, the mothers were asked to fetch the index child s health record. Moreover, completion of the health record, especially for birth-related characteristics (birth weight 5 12 and gestational age), was independent of the case/control status. Only 10 case mothers (5 ) 
The literature on birth-related characteristics is still inconsistent. Both, low birth weight , , and high birth weight , have been 5 6 8 7 9
positively associated with neuroblastoma, but five other studies did not detect any association. , As was the case in the present 4 10-13 study, most studies have not evidenced any association with gestational age, even though others have shown a positive association or a 5 negative association , with pre-term birth (< 37 weeks). The negative association between neuroblastoma and high birth order observed 4 8 in the present study is in line with the findings of two other studies. , It has been suggested that the hygiene hypothesis proposed with 4 13
" "
respect to childhood acute leukemia should also be considered for neuroblastoma. , 31 32 33
A potential drawback of case-control studies is the lack of reliability, possibly differential, of maternal recall. Since the congenital malformation data were obtained by interviewing case and control mothers and not from medical records, there was an opportunity for a recall bias to occur. The results of the present study may be explained by over-declaration of malformations by case mothers or under-declaration by control mothers. However, the results remained the same when the analyses were restricted to malformations considered major by EUROCAT which are less liable to differential recall bias.27
Another concern is that the observed association between congenital anomalies and neuroblastoma may be the consequence of over-detection of asymptomatic anomalies in the course of disease staging. However, the medical records of 9 out of 12 cases with a malformation were checked (the 3 remaining medical records were not available). All the malformations were diagnosed before the neuroblastoma and all the diagnoses were the same as those reported by the mothers. In addition, associations remained unchanged after excusion of cases whose malformation was not validated and thus, specifically for children aged less than 1 year (any malformation: OR= 12.3 2.1 71 , major malformation: OR 23.1 2.5 214 ). Nevertheless, we can not completely rule out that some neuroblastoma cases may
have been diagnosed in the process of evaluating a child with a known malformation.
The relationship found between neuroblastoma and congenital malformation is consistent with most of the previous studies, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] although no cardiovascular malformations were observed in the cases. , , , , , Those previous studies used different methods to 15 17 19 22 34 35 assess congenital malformations (medical records, birth certificates and hospital records, birth defect registries and parental self-report) which may have led to various potential biases.
Our results may be an argument for the involvement of developmental genes in neuroblastoma. Indeed, the PHOX2B gene, a human development gene, has already been associated with Congenital Central Hypoventilation Syndrome (CCHS, or Ondine s curse) which, like ' neuroblastoma, is a disorder of autonomic nervous system development. The specific association between neuroblastoma and congenital 35 malformation in infants has also been observed in a recent study based on birth certificates and hospital records.22
Maternal reproductive history has rarely been investigated in the literature and the terminology used in the various studies does not always enable spontaneous abortions, abortions and termination of pregnancy for medical reasons to be distinguished. The terms used by the mothers themselves are probably not always reliable but they are likely to be similarly used by the cases and controls. Most previous studies did not find any association with fetal losses overall, , , induced abortions, or spontaneous abortions. Nonetheless, one study 5 6 13 4 4
reported a negative association between neuroblastoma and all fetal losses, two studies found a positive association with prior 11 spontaneous abortions , and one study also found a positive association with induced abortions. 10 12 10 In contrast, in the present study, a relatively strong inverse association with maternal history of spontaneous abortions was observed and that association decreased as the number of miscarriages increased (p 0.01).
=
Over the last 30 years, rapid advances have been made in the treatment of infertility. While the effects of infertility treatments on birth and short-term outcomes are relatively well documented, little is known about potential effects on child health after the neonatal period.
Childhood cancer and especially neuroblastoma, which may be initiated during the early stages of fetal development, may be a possible adverse outcome of the use of infertility treatments. Indeed, out of five case-control studies, three reported a positive association with the use of sex hormone exposure for infertility (induction of ovulation), one reported a non significant association and one did not 37-39 40 find any association. Moreover, among six cohort studies investigating the incidence of childhood cancer in children born following 12 infertility treatments, two found an elevated, but non-significant, SIR for neuroblastoma and, interestingly, one study did not 41-46 401, 42
find any association with childhood cancer but did detect an association with congenital anomalies.45
In conclusion, our results strongly support the hypothesis that congenital anomalies may be associated with neuroblastoma, particularly in children aged less than 1 year.
Ackowledgements:
inserm-00260711, version 1 -4 Sep 2009 6 12 This work was supported by grants from INSERM, the Fondation de France, the Association pour la Recherche contre le Cancer (ARC), the Agence Fran aise de S curit Sanitaire des Produits de Sant (AFSSAPS), the Agence Fran aise de S curit Sanitaire de I Environnement et
du Travail (AFSSET) and the association Cent pour Sang la Vie. who determined the MYCN copy numbers; and Andrew Mullarky for his skilful revision of the manuscript.
Footnotes:
*SFCE: Soci t Fran aise de lutte contre les Cancers de l Enfant et de I adolescent
This paper investigated the role of perinatal factors (birth weight, birth order, congenital anomalies, Novelty and impact of our paper: spontaneous abortion and the use of fertility treatments) in children with neuroblastoma in France at a national scale. We report that congenital malformations were more frequent in neuroblastoma cases than in population controls, and particularly for children aged less than 1 year which has nerver been described before. 26. Steliarova 
